Compare FULC & NCV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | FULC | NCV |
|---|---|---|
| Founded | 2015 | 2003 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Finance Companies |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 281.1M | 337.1M |
| IPO Year | 2019 | N/A |
| Metric | FULC | NCV |
|---|---|---|
| Price | $3.69 | $13.32 |
| Analyst Decision | Hold | |
| Analyst Count | 5 | 0 |
| Target Price | ★ $3.67 | N/A |
| AVG Volume (30 Days) | ★ 1.2M | 62.4K |
| Earning Date | 11-12-2026 | 01-01-0001 |
| Dividend Yield | N/A | ★ 12.48% |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $2.83 | $13.55 |
| 52 Week High | $15.74 | $17.65 |
| Indicator | FULC | NCV |
|---|---|---|
| Relative Strength Index (RSI) | 45.53 | 23.84 |
| Support Level | $3.62 | N/A |
| Resistance Level | $3.81 | $16.75 |
| Average True Range (ATR) | 0.06 | 0.32 |
| MACD | -0.00 | -0.12 |
| Stochastic Oscillator | 7.69 | 3.48 |
Fulcrum Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing small molecules for genetically defined rare diseases. Its product candidate, Pociredir, is an oral small molecule designed to induce fetal hemoglobin (HbF) and is in clinical development for sickle cell disease (SCD). The company completed dosing in the Phase 1b PIONEER trial evaluating pociredir in adults with SCD and reported clinical data showing clinically relevant HbF induction and improvements in markers of hemolysis and anemia. The company has also generated a pipeline of clinical-stage and pre-clinical programs targeting the root causes of rare genetic diseases.
Virtus Convertible & Income Fund is a diversified, closed-end management investment company. Its investment objective is to provide total return through a combination of current income, current gains and long-term capital appreciation. It intends to achieve the objective by investing in a portfolio of domestic convertible securities and non-convertible income-producing securities. Its portfolio of investments includes Software, the Internet, the Commercial Services sector in the form of Convertible Bonds and Notes, and Media, Oil, Gas & Consumable Fuels, and Entertainment sector in the form of Corporate Bonds and Notes.